



FDA ADVISORY
No. **2020-204**

26 FEB 2020

TO: GENERAL CONSUMING PUBLIC

SUBJECT: Public Health Warning Against the Purchase and Use of Cosmetic Product "BRILLIANT SKIN ESSENTIALS REJUVENATING FACIAL CREAM" Containing Banned Ingredient/s

The Food and Drug Administration (FDA) warns the public from purchasing and using the adulterated cosmetic product **BRILLIANT SKIN ESSENTIALS REJUVENATING FACIAL CREAM** which tested positive for the presence of **HYDROQUINONE** and **TRETINOIN**. Such ingredients are not allowed to be part of a cosmetic product as per Annex II Part 1 of the ASEAN Cosmetic Directive. The table below indicates the particulars of the adulterated cosmetic product:

PRODUCT DETAILS	PRODUCT IMAGE/S
Manufactured by/ Local Company Responsible for Placing the Product in the Market: Brilliant Skin Essentials	
Address: 35 J. Sta. Catalina St., Sitio Caingin, Brgy. San Juan, Morong, Rizal	
Country of Manufacture: Philippines	
Lot/Batch Number: RFC0063:10/15 Mfg. Date: 10/19 Exp. Date: 10/21	

Products containing Hydroquinone and/or Tretinoin (Retinoic Acid) shall be classified as home remedy, over-the-counter, or prescription drug depending on the amount present as per Administrative Order No. 13 s. 1999.



The aforementioned adulterated product is found to be non-compliant with the existing standards, and, thus pose potential hazards to the consuming public. The use of adulterated cosmetic products may result to adverse reactions, including but not limited to, skin irritation, itchiness, anaphylactic shock and organ failure.

In light of the foregoing, the public is advised not to purchase the aforementioned adulterated product. Moreover, the public is advised to always check if a cosmetic product is notified with the FDA. The FDA website (www.fda.gov.ph) has a *Search* feature which may be used by typing in the name of the product before purchasing.


All concerned establishments are warned not to distribute adulterated cosmetic products.

All FDA Regional Field Offices and Regulatory Enforcement Units, in coordination with law enforcement agencies and Local Government Units, are requested to ensure that violative products are not sold or made available in the market or areas of jurisdiction.

Kindly contact the FDA Center for Cosmetics Regulation and Research through e-mail at crr@fda.gov.ph, or call (02) 8857-1900 loc. 8113 or 8107.

To report any sale or distribution of the aforementioned cosmetic product, the online reporting facility, **eReport** can be accessed at www.fda.gov.ph/ereport.

Dissemination of this advisory to all concerned is hereby requested.


ROLANDO ENRIQUE D. DOMINGO, MD, DPBO
Undersecretary of Health
Officer-in-Charge, Director General

DTN 20200218142729